Brevets | Allurion Elipse Ballon Gastrique

Choose your country or region in order to display more relevant content.

Select

Other country or region

Country

Language

Continuer

Les produits Allurionᴹᴰ sont protégés aux États-Unis et à l’échelle internationale par les brevets suivants :

Brevets américains, Ballon gastrique Elipseᴹᴰ (toutes versions confondues) :

Brevet américain nº8814898

Brevet américain nº8870907

Brevet américain nº8974483

Brevet américain nº9387107

Brevet américain nº9827129

Brevet américain nº10182932

Autres brevets américains :

Brevet américain nº9849018

Brevet américain nº 10307279

Brevet américain nº 10470908

Brevet américain nº 10588768

Brevet américain nº 10583024

Brevets internationaux, Ballon gastrique Elipseᴹᴰ (toutes versions confondues) :

Australie

AU 2013222419

AU 2014342014

AU 2017204386

Chine

ZL 2013 8 00104184

ZL 2014 8 0071908.X

France

EP2817062

EP3189817

Allemagne

DE 60 2013 013 543.6

DE 60 2013 045 422.1

Irlande

EP2817062

EP3189817

Israël

IL 234139

Italie

EP 2817062

EP 3189817

Japonais

JP 6311936

Corée (République de)

KR 10-1872064

Mexique

MX 349195

Russie

RU 2601995

Singapour

SG 11201404821U

Espagne

EP2817062

EP3189817

Royaume-Uni

EP2817062

EP3189817

Autres brevets internationaux :

France

EP2916904

Allemagne

DE 60 2013 035 222.4

Irlande

EP2916904

Royaume-Uni

EP2916904

*As with any medical solution, results may vary from one patient to another, and some patients may not respond to treatment. Please consult a doctor to carefully evaluate the risks and benefits before making your decision.
**The removal of the Allurion Balloon may, in very rare cases, require an endoscopic or surgical intervention. In rare cases, instead of being expelled through the digestive tract, the empty balloon may be vomited out.
***Eligibility for the placement of an Allurion Balloon will be assessed by a certified doctor after an initial consultation and a careful review of your medical history. In the case of an extended Allurion Program, your eligibility is reassessed before each placement to ensure you continue to meet the required conditions.

R. Ienca et al. The procedureless ellipse gastric balloon program: Multicenter experience in 1770 consecutive patients. Obes surg. 2020;30(9):3354-3362. Multicenter, prospective, non-randomized, open registry study conducted in patients with overweight or obesity from January 2016 to June 2019 in 19 international obesity centers participating in the study. A total of 1,770 patients with an average BMI of 34.4 ± 5.3 kg/m2 at baseline underwent treatment with the Elipse swallowable gastric balloon, with a monthly visit and a total follow-up of 4 months. 63 patients (3.6%) did not complete the program, and the balloon was removed before 4 months due to intolerance or other adverse effects.
World Health Organization – Key facts on Obesity and overweight (who.int).
European survey finds over three-quarters of adults with obesity have attempted to lose weight in the past year, but most have been unsuccessful – EASO.
This information is extracted from the instructions for use of the Allurion Gastric Balloon System. Version number CS137-02-ENG. If you have any questions regarding this document, please consult your doctor....

Chat with Ally